Cerebellar tDCS + Language Therapy for Aphasia
(CeSAR Trial)
Trial Summary
What is the purpose of this trial?
The optimal site of neuromodulation for post-stroke aphasia has yet to be established. This study will investigate whether multiple sessions of cerebellar transcranial direct current stimulation (tDCS) boosts language therapy in helping people recover from aphasia as well as predict who is likely to respond to cerebellar tDCS.
Do I need to stop taking my current medications for the trial?
You may need to stop taking certain medications, especially those that lower the seizure threshold or NMDA antagonists, as they are listed in the exclusion criteria.
What data supports the effectiveness of the treatment Cathodal Cerebellar tDCS for aphasia?
Research shows that cathodal tDCS can improve language abilities in post-stroke aphasic patients, such as enhancing picture naming accuracy by 33.6%. Additionally, tDCS has been found to augment language outcomes in aphasia, suggesting it may be a useful tool when combined with language therapy.12345
Is cathodal cerebellar tDCS safe for humans?
How does the cerebellar tDCS + language therapy treatment for aphasia differ from other treatments?
Cerebellar tDCS (transcranial direct current stimulation) combined with language therapy is unique because it targets the cerebellum, a part of the brain not traditionally associated with language, to enhance language recovery in aphasia patients. This approach is novel as it uses electrical stimulation to potentially improve language skills more effectively than standard language therapy alone, especially for untrained language tasks.128910
Research Team
Rajani Sebastian, PhD
Principal Investigator
Johns Hopkins University
Eligibility Criteria
This trial is for English-speaking adults over 18 who had a stroke in the left hemisphere of their brain at least 6 months ago, resulting in aphasia and difficulty naming things. They must have been right-handed before the stroke. People with cerebellum damage, other neurological or psychiatric disorders, recent seizures, severe sensory loss, certain medication use, high baseline naming test scores, metal in their head or body implants are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 15 sessions of cerebellar tDCS combined with Semantic Feature Analysis (SFA) over 3-5 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Cathodal Cerebellar tDCS
Find a Clinic Near You
Who Is Running the Clinical Trial?
Johns Hopkins University
Lead Sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
Collaborator